Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLLNASDAQ:KRYSNASDAQ:PTCTNASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$28.86+0.1%$28.11$23.23▼$42.29$927.33M0.63427,547 shs178,265 shsKRYSKrystal Biotech$125.05-0.2%$162.61$123.12▼$219.34$3.61B0.79307,417 shs298,645 shsPTCTPTC Therapeutics$45.93+0.9%$47.39$28.72▼$58.38$3.64B0.52857,058 shs782,553 shsSRPTSarepta Therapeutics$37.90-2.3%$54.60$34.10▼$173.25$3.72B0.851.78 million shs2.05 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-2.21%-1.77%+7.18%-1.06%-15.68%KRYSKrystal Biotech-1.10%-3.87%-25.78%-33.31%-25.97%PTCTPTC Therapeutics-1.49%+0.46%-5.54%-10.20%+17.81%SRPTSarepta Therapeutics-3.15%+9.98%-34.60%-63.50%-69.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.0229 of 5 stars3.40.00.03.04.00.82.5KRYSKrystal Biotech4.9028 of 5 stars4.52.00.04.74.03.31.9PTCTPTC Therapeutics4.1684 of 5 stars4.33.00.04.42.70.80.0SRPTSarepta Therapeutics4.7635 of 5 stars4.42.00.04.23.22.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.80Moderate Buy$43.8051.77% UpsideKRYSKrystal Biotech 3.00Buy$211.1368.83% UpsidePTCTPTC Therapeutics 2.64Moderate Buy$63.2537.71% UpsideSRPTSarepta Therapeutics 2.83Moderate Buy$122.61223.51% UpsideCurrent Analyst Ratings BreakdownLatest COLL, KRYS, SRPT, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$40.00 ➝ $40.005/20/2025SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$169.00 ➝ $84.005/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/8/2025SRPTSarepta TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy$188.00 ➝ $85.005/8/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$115.00 ➝ $100.005/8/2025SRPTSarepta TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline$50.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.005/7/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.00 ➝ $219.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$664.28M1.40$10.46 per share2.76$5.99 per share4.82KRYSKrystal Biotech$333.45M10.84$3.18 per share39.38$32.85 per share3.81PTCTPTC Therapeutics$1.77B2.05$2.21 per share20.80($10.85) per share-4.23SRPTSarepta Therapeutics$2.23B1.67N/AN/A$9.19 per share4.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$48.15M$1.2212.444.79N/A14.78%104.67%18.38%N/AKRYSKrystal Biotech$10.93M$4.1641.8212.41N/A30.69%11.41%10.40%8/4/2025 (Estimated)PTCTPTC Therapeutics-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%N/ASRPTSarepta Therapeutics-$535.98M-$2.6930.323.46N/A7.43%11.00%3.35%8/6/2025 (Estimated)Latest COLL, KRYS, SRPT, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million2/27/2025Q4 2024COLLCollegium Pharmaceutical$1.54$1.63+$0.09$0.36$179.68 million$181.95 million2/24/2025Q4 2024KRYSKrystal Biotech$1.29$1.52+$0.23$1.52$91.35 million$91.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.430.970.88KRYSKrystal BiotechN/A7.287.76PTCTPTC TherapeuticsN/A2.102.04SRPTSarepta Therapeutics0.933.843.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AKRYSKrystal Biotech86.29%PTCTPTC TherapeuticsN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%KRYSKrystal Biotech13.70%PTCTPTC Therapeutics5.50%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million30.97 millionOptionableKRYSKrystal Biotech21028.90 million24.71 millionOptionablePTCTPTC Therapeutics1,41079.26 million72.88 millionOptionableSRPTSarepta Therapeutics84098.28 million88.17 millionOptionableCOLL, KRYS, SRPT, and PTCT HeadlinesRecent News About These CompaniesSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23 at 3:16 PM | benzinga.comSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23 at 3:16 PM | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up - Still a Buy?May 23 at 10:41 AM | marketbeat.comJPMorgan Chase & Co. Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $84.00May 23 at 2:29 AM | americanbankingnews.comFDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne studyMay 22 at 11:41 AM | biopharmadive.comSarepta Can Start Dosing Elevidys Trial, UK Regulators SayMay 22 at 11:41 AM | precisionmedicineonline.comSarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study ContinueMay 21 at 3:37 PM | marketwatch.comSarepta, Roche get U.K. feedback to lift clinical hold on Elevidys' Duchenne trialMay 21 at 3:37 PM | msn.comSarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in DuchenneMay 21 at 3:37 PM | finance.yahoo.comSarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular DystrophyMay 21 at 9:08 AM | businesswire.comVestal Point Capital LP Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 21 at 8:14 AM | marketbeat.comTriglav Skladi D.O.O. Invests $1.34 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 21 at 6:55 AM | marketbeat.comNuveen Asset Management LLC Increases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 21 at 4:55 AM | marketbeat.comSarepta Shares Higher After J.P. Morgan NoteMay 20 at 4:11 PM | marketwatch.comSRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative DelaysMay 20 at 8:24 AM | msn.comSummit Partners Public Asset Management LLC Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 19, 2025 | marketbeat.comSuvretta Capital Management LLC Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 19, 2025 | marketbeat.comRafferty Asset Management LLC Sells 28,806 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 19, 2025 | marketbeat.comSphera Funds Management LTD. Has $12.03 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 18, 2025 | marketbeat.comSarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of TreatmentMay 16, 2025 | finance.yahoo.comNovartis, Sarepta tipped to drive genomic therapy sales toward $90BMay 15, 2025 | fiercepharma.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreBy Sam Quirke | May 14, 2025View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore3 Stocks Presenting Generational Buying OpportunitiesBy Chris Markoch | April 25, 2025View 3 Stocks Presenting Generational Buying OpportunitiesHims & Hers Stock Soars on Novo Nordisk CollaborationBy Gabriel Osorio-Mazilli | April 30, 2025View Hims & Hers Stock Soars on Novo Nordisk CollaborationCOLL, KRYS, SRPT, and PTCT Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$28.86 +0.04 (+0.14%) Closing price 04:00 PM EasternExtended Trading$28.80 -0.06 (-0.22%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Krystal Biotech NASDAQ:KRYS$125.05 -0.24 (-0.19%) Closing price 04:00 PM EasternExtended Trading$125.04 -0.01 (-0.01%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.PTC Therapeutics NASDAQ:PTCT$45.93 +0.41 (+0.90%) Closing price 04:00 PM EasternExtended Trading$45.61 -0.32 (-0.70%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Sarepta Therapeutics NASDAQ:SRPT$37.90 -0.89 (-2.29%) Closing price 04:00 PM EasternExtended Trading$38.08 +0.19 (+0.49%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
